Aricept®
Donepezil
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$400+ (brand historical)
With Insurance
$5–25 (generic)
The Short Version
Evidence summary
Aricept (Donepezil) is a Cholinesterase Inhibitor prescribed for Mild to moderate Alzheimer's disease and Severe Alzheimer's disease (23mg dose). FDA-approved in November 1996.
The most commonly reported side effects are Nausea (11%), Diarrhea (10%), Insomnia (9%). Take with food; usually improves after first few weeks
Research includes independent, publicly funded studies.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$38
$15 w/ insurance
without insurance
Annual
$456
$180 w/ insurance
without insurance
10 Years
$4.6K
$1.8K w/ insurance
without insurance
30 Years
$13.7K
$5.4K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Aerobic Exercise (150 min/week) — Meta-analyses show aerobic exercise improves cognitive function in MCI patients by 0.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
CMS MAHA ELEVATE
This medication has lifestyle alternatives supported by evidence
See how EvidentMeds supports the CMS MAHA ELEVATE program for clinicians
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
Related Evidence
Explore related medications reviewed on EvidentMeds
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Cognitive Preservation: Addressing Root Causes of Neurodegeneration
Donepezil does not slow, halt, or reverse Alzheimer's — it modestly delays symptom progression by increasing available acetylcholine. The root drivers of neurodegeneration include insulin resistance (sometimes called "Type 3 diabetes"), chronic neuroinflammation, poor sleep, and physical inactivity. Emerging evidence suggests these modifiable factors may be more impactful than any current medication.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Aerobic Exercise (150 min/week)
Exercise increases BDNF (brain-derived neurotrophic factor), improves cerebral blood flow, and reduces neuroinflammation — mechanisms no drug currently replicates
Meta-analyses show aerobic exercise improves cognitive function in MCI patients by 0.5–1.0 SD; comparable to or exceeding donepezil effect sizes. Also reduces fall risk — a major concern in dementia patients.
Mediterranean / MIND Diet
Rich in polyphenols, omega-3s, and anti-inflammatory compounds; reduces oxidative stress and neuroinflammation
MIND diet associated with 53% reduced AD risk in observational studies; high adherence equivalent to being 7.5 years younger cognitively. Rush University longitudinal data.
Cognitive Stimulation Therapy (CST)
Structured group activities targeting cognitive and social engagement — the most evidence-based non-drug dementia intervention
NICE-recommended; RCTs show cognitive improvements equivalent to cholinesterase inhibitors, with additional quality-of-life benefits and no side effects. Endorsed by UK NHS.
Sleep Optimization
Poor sleep increases amyloid-beta accumulation — the glymphatic system clears brain waste during deep sleep
Chronic sleep disruption increases AD risk 1.5–2×; treating sleep apnea and optimizing sleep architecture may slow cognitive decline independently of medication.
Key Studies
Global Prescribing & Pricing
Donepezil is the most prescribed dementia drug globally — but independent trials suggest more modest benefits than marketing implies
United States
$15–60 (generic)/mo
Very widely prescribed; often started at diagnosis
No requirement for non-pharmacological interventions first; prescribed reflexively at diagnosis in many settings
Covered by most plans; generic pricing makes cost a non-issue
United Kingdom
~$5–10/mo
NICE recommends for mild-to-moderate AD alongside cognitive stimulation
Must be prescribed by specialist; cognitive stimulation therapy offered alongside
NHS covered with specialist initiation
Germany
~$10–20/mo
First-line for mild-moderate AD
Non-pharmacological interventions (occupational therapy, cognitive training) typically offered concurrently
GKV covered
Japan
~$15–30/mo
Eisai is Japanese — very high adoption domestically
Comprehensive dementia care plans required alongside medication
NHI covered
Donepezil is inexpensive as a generic, so the cost issue is less about price and more about whether the modest cognitive benefit justifies the side effect burden — especially when non-pharmacological approaches (cognitive stimulation, exercise, social engagement) show comparable or better outcomes in some studies.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
The original FDA-approval trials were funded entirely by Eisai. The independent, publicly-funded AD2000 trial (UK NHS, 2004) found donepezil provided statistically significant but clinically modest benefits — patients gained about 0.8 MMSE points over 2 years with no delay in institutionalization. Despite this, Eisai marketed the drug aggressively, generating over $3 billion in peak annual sales.
Declared Conflicts of Interest
Eisai and Pfizer co-promoted Aricept as a breakthrough, though the AD2000 trial (independent of industry funding) showed far more modest real-world effects than industry trials suggested. Many KOL dementia researchers who advocated for aggressive early treatment had financial relationships with Eisai/Pfizer.
Key Efficacy Results
Modest cognitive improvement: ~1.5–2.5 MMSE points in industry trials, ~0.8 points in independent AD2000; does not reverse or halt disease progression; symptomatic benefit only
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Donepezil. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Donepezil in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| AD2000 Trial (Independent) | PMID:15141041 | |
| Eisai Phase III (Mild-Moderate AD) | PMID:9651245 | |
| Cochrane Review: Donepezil | PMID:16437532 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Nausea
11%Take with food; usually improves after first few weeks
Diarrhea
10%Stay hydrated; report persistent diarrhea — may worsen dehydration in elderly
Insomnia
9%Take in the morning rather than evening
Muscle cramps
6%Magnesium supplementation may help; stretch before bed
Fatigue / dizziness
5%Rise slowly; usually transient during dose titration
Serious Adverse Effects
- • Bradycardia — can cause dangerous slowing of heart rate, especially with beta-blockers or calcium channel blockers
- • Seizures — cholinesterase inhibitors lower seizure threshold
- • GI bleeding — increased gastric acid secretion; risk amplified by NSAIDs or anticoagulants
- • Urinary obstruction — cholinergic effects can worsen bladder outlet obstruction
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Bradycardia — can cause dangerous slowing of heart rate, especially with beta-blockers or calcium channel blockers
- Seizures — cholinesterase inhibitors lower seizure threshold
- GI bleeding — increased gastric acid secretion; risk amplified by NSAIDs or anticoagulants
- Urinary obstruction — cholinergic effects can worsen bladder outlet obstruction
- Increased confusion or agitation
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
No adequate human studies. Not typically relevant since Alzheimer's onset is post-reproductive age.
Unknown excretion in breast milk. Not typically relevant clinically.
Donepezil is not indicated for pediatric use.
Most patients are elderly. Monitor for falls (dizziness), bradycardia, and GI side effects. Ensure not on anticholinergics simultaneously — this is extremely common in elderly polypharmacy.
Renal impairment does not significantly affect donepezil clearance.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Donepezil does not cause physical dependence, but abrupt discontinuation may cause noticeable cognitive and functional decline within weeks. Whether this represents genuine withdrawal or simply loss of symptomatic support is debated.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Discuss with prescriber — stopping may cause noticeable cognitive decline
- ·If stopping, consider gradual reduction (10mg → 5mg for 2–4 weeks, then stop)
- ·Monitor closely for behavioral changes, increased confusion, or functional decline for 4–6 weeks
- ·Ensure non-pharmacological supports (cognitive stimulation, structured routine) are in place before stopping
Warning Symptoms — Contact Your Doctor If You Experience:
- Increased confusion or agitation
- Rapid cognitive decline
- Behavioral changes (aggression, wandering)
- Sleep disruption
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Are there anticholinergic medications on my list that are working against this drug?
- 2.What is the realistic expected benefit — and how will we measure whether it's working?
- 3.Should we also be doing cognitive stimulation therapy or structured exercise alongside this?
- 4.At what point should we consider stopping if there's no measurable benefit?
- 5.Is the 23mg dose justified, given the higher side effect rates?
Lab Tests to Request
- MMSE or MoCA baseline and every 6 months
- ECG if on beta-blockers or history of bradycardia
- Comprehensive medication review for anticholinergic burden
- Nutritional assessment
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Aricept®
- What is Aricept® used for?
- Aricept® (Donepezil) is a Cholinesterase Inhibitor manufactured by Eisai / Pfizer (now generic). FDA-approved indications include: Mild to moderate Alzheimer's disease; Severe Alzheimer's disease (23mg dose); Dementia symptom management.
- What are the common side effects of Aricept®?
- Common side effects of Aricept® include: Nausea (11%); Diarrhea (10%); Insomnia (9%); Muscle cramps (6%); Fatigue / dizziness (5%).
- How much does Aricept® cost?
- Aricept® list price is approximately $400+ (brand historical). With insurance it typically costs $5–25 (generic); without insurance approximately $15–60 (generic).
- Who funded the clinical trials for Aricept®?
- The original FDA-approval trials were funded entirely by Eisai. The independent, publicly-funded AD2000 trial (UK NHS, 2004) found donepezil provided statistically significant but clinically modest benefits — patients gained about 0.8 MMSE points over 2 years with no delay in institutionalization. Despite this, Eisai marketed the drug aggressively, generating over $3 billion in peak annual sales.
- How strong is the clinical evidence for Aricept®?
- Key studies: AD2000 (UK public-funded), Eisai Phase III trials (1996), Cochrane systematic reviews. Modest cognitive improvement: ~1.5–2.5 MMSE points in industry trials, ~0.8 points in independent AD2000; does not reverse or halt disease progression; symptomatic benefit only Potential conflicts of interest: Eisai and Pfizer co-promoted Aricept as a breakthrough, though the AD2000 trial (independent of industry funding) showed far more modest real-world effects than industry trials suggested. Many KOL dem.
- Are there non-drug alternatives to Aricept®?
- Donepezil does not slow, halt, or reverse Alzheimer's — it modestly delays symptom progression by increasing available acetylcholine. The root drivers of neurodegeneration include insulin resistance (sometimes called "Type 3 diabetes"), chronic neuroinflammation, poor sleep, and physical inactivity. See the Alternatives tab for full details.
Get notified when we update Aricept®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.